Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...

Cablivi is the first nanobody-based medicine from the French pharma’s pipeline to receive regulatory approval. The drug will be a part of Sanofi Genzyme’s Rare Blood Disorders franchise ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

“The Gaucher Initiative has empowered the diagnosis and management of this rare disease in Egypt, aiming that no patient is left behind.” Beyond Gaucher disease, Sanofi's Rare Humanitarian ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment ... Further boosting the ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Sanofi's late-stage pipeline doesn't hold a large number ... Sanofi’s entrenched rare-disease drug, consumer, and vaccine franchises create added layers of competitive advantages, stemming ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.